生物
免疫球蛋白E
食物过敏
免疫系统
过敏
免疫疗法
免疫学
过敏原
免疫耐受
发病机制
抗体
作者
Suzanne Barshow,Jyothi Tirumalasetty,Vanitha Sampath,Xiaoying Zhou,Hana Seastedt,Jackson Schuetz,Kari C. Nadeau
标识
DOI:10.1146/annurev-immunol-090122-043501
摘要
IgE-mediated food allergy (IgE-FA) occurs due to a breakdown in immune tolerance that leads to a detrimental type 2 helper T cell (TH2) adaptive immune response. While the processes governing this loss of tolerance are incompletely understood, several host-related and environmental factors impacting the risk of IgE-FA development have been identified. Mounting evidence supports the role of an impaired epithelial barrier in the development of IgE-FA, with exposure of allergens through damaged skin and gut epithelium leading to the aberrant production of alarmins and activation of TH2-type allergic inflammation. The treatment of IgE-FA has historically been avoidance with acute management of allergic reactions, but advances in allergen-specific immunotherapy and the development of biologics and other novel therapeutics are rapidly changing the landscape of food allergy treatment. Here, we discuss the pathogenesis and immunobiology of IgE-FA in addition to its diagnosis, prognosis, and treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI